.Pharmacolibrary.Drugs.ATC.N.N03AX23 .Pharmacolibrary.Drugs.ATC.N.N03AX23| name: | Brivaracetam |
| ATC code: | N03AX23 | route: | oral |
| n-compartments | 1 |
Brivaracetam is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy. It is a high-affinity ligand for synaptic vesicle protein 2A (SV2A) and is approved for use in several countries, including the US and EU.
Pharmacokinetic parameters reported in healthy adult subjects (both sexes, ages 18-65) after oral administration.
Klein, P, & Bourikas, D (2024). Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. Advances in therapy 41(7) 2682–2699. DOI:10.1007/s12325-024-02876-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/38811492
Schoemaker, R, et al., & Stockis, A (2017). Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. European journal of clinical pharmacology 73(6) 727–733. DOI:10.1007/s00228-017-2230-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28280887
Stockis, A, et al., & Krauwinkel, W (2023). Pharmacokinetics, Safety, and Tolerability of Brivaracetam in Healthy Elderly Participants. Clinical pharmacology in drug development 12(11) 1121–1127. DOI:10.1002/cpdd.1264 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37212183